These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 23443946)
1. Androgen receptor protein levels are significantly reduced in serous ovarian carcinomas compared with benign or borderline disease but are not altered by cancer stage or metastatic progression. Butler MS; Ricciardelli C; Tilley WD; Hickey TE Horm Cancer; 2013 Jun; 4(3):154-64. PubMed ID: 23443946 [TBL] [Abstract][Full Text] [Related]
2. Small glutamine-rich tetratricopeptide repeat-containing protein alpha is present in human ovaries but may not be differentially expressed in relation to polycystic ovary syndrome. Butler MS; Yang X; Ricciardelli C; Liang X; Norman RJ; Tilley WD; Hickey TE Fertil Steril; 2013 Jun; 99(7):2076-83.e1. PubMed ID: 23433514 [TBL] [Abstract][Full Text] [Related]
3. Molecular cloning of canine co-chaperone small glutamine-rich tetratricopeptide repeat-containing protein α (SGTA) and investigation of its ability to suppress androgen receptor signalling in androgen-independent prostate cancer. Kato Y; Ochiai K; Michishita M; Azakami D; Nakahira R; Morimatsu M; Ishiguro-Oonuma T; Yoshikawa Y; Kobayashi M; Bonkobara M; Kobayashi M; Takahashi K; Watanabe M; Omi T Vet J; 2015 Nov; 206(2):143-8. PubMed ID: 26346258 [TBL] [Abstract][Full Text] [Related]
4. Subdomain structure of the co-chaperone SGTA and activity of its androgen receptor client. Trotta AP; Need EF; Butler LM; Selth LA; O'Loughlin MA; Coetzee GA; Tilley WD; Buchanan G J Mol Endocrinol; 2012 Oct; 49(2):57-68. PubMed ID: 22693264 [TBL] [Abstract][Full Text] [Related]
5. Canine REIC/Dkk-3 interacts with SGTA and restores androgen receptor signalling in androgen-independent prostate cancer cell lines. Kato Y; Ochiai K; Kawakami S; Nakao N; Azakami D; Bonkobara M; Michishita M; Morimatsu M; Watanabe M; Omi T BMC Vet Res; 2017 Jun; 13(1):170. PubMed ID: 28599655 [TBL] [Abstract][Full Text] [Related]
6. Knockdown of the cochaperone SGTA results in the suppression of androgen and PI3K/Akt signaling and inhibition of prostate cancer cell proliferation. Trotta AP; Need EF; Selth LA; Chopra S; Pinnock CB; Leach DA; Coetzee GA; Butler LM; Tilley WD; Buchanan G Int J Cancer; 2013 Dec; 133(12):2812-23. PubMed ID: 23740762 [TBL] [Abstract][Full Text] [Related]
7. Tumor suppressor REIC/DKK-3 and co-chaperone SGTA: Their interaction and roles in the androgen sensitivity. Ochiai K; Morimatsu M; Kato Y; Ishiguro-Oonuma T; Udagawa C; Rungsuriyawiboon O; Azakami D; Michishita M; Ariyoshi Y; Ueki H; Nasu Y; Kumon H; Watanabe M; Omi T Oncotarget; 2016 Jan; 7(3):3283-96. PubMed ID: 26658102 [TBL] [Abstract][Full Text] [Related]
8. Evidence for the multifocal origin of bilateral and advanced human serous borderline ovarian tumors. Lu KH; Bell DA; Welch WR; Berkowitz RS; Mok SC Cancer Res; 1998 Jun; 58(11):2328-30. PubMed ID: 9622067 [TBL] [Abstract][Full Text] [Related]
9. [Expression and promotor methylation of p73 gene in ovarian epithelial tumors]. Zhang YL; Guo XR; Shen DH; Cheng YX; Liang XD; Chen YX; Wang Y Zhonghua Bing Li Xue Za Zhi; 2012 Jan; 41(1):33-8. PubMed ID: 22455848 [TBL] [Abstract][Full Text] [Related]
10. The cochaperone SGTA (small glutamine-rich tetratricopeptide repeat-containing protein alpha) demonstrates regulatory specificity for the androgen, glucocorticoid, and progesterone receptors. Paul A; Garcia YA; Zierer B; Patwardhan C; Gutierrez O; Hildenbrand Z; Harris DC; Balsiger HA; Sivils JC; Johnson JL; Buchner J; Chadli A; Cox MB J Biol Chem; 2014 May; 289(22):15297-308. PubMed ID: 24753260 [TBL] [Abstract][Full Text] [Related]
11. Genetic alterations of serous borderline tumors of the ovary compared to stage I serous ovarian carcinomas. Osterberg L; Akeson M; Levan K; Partheen K; Zetterqvist BM; Brännström M; Horvath G Cancer Genet Cytogenet; 2006 Jun; 167(2):103-8. PubMed ID: 16737908 [TBL] [Abstract][Full Text] [Related]
12. Control of androgen receptor signaling in prostate cancer by the cochaperone small glutamine rich tetratricopeptide repeat containing protein alpha. Buchanan G; Ricciardelli C; Harris JM; Prescott J; Yu ZC; Jia L; Butler LM; Marshall VR; Scher HI; Gerald WL; Coetzee GA; Tilley WD Cancer Res; 2007 Oct; 67(20):10087-96. PubMed ID: 17942943 [TBL] [Abstract][Full Text] [Related]
13. Clinical factors and biomarkers in ovarian tumors development. Vrabie CD; Petrescu A; Waller M; Dina I Rom J Morphol Embryol; 2008; 49(3):327-38. PubMed ID: 18758637 [TBL] [Abstract][Full Text] [Related]
14. An immunohistochemical evaluation of androgen and progesterone receptors in ovarian tumors. Chadha S; Rao BR; Slotman BJ; van Vroonhoven CC; van der Kwast TH Hum Pathol; 1993 Jan; 24(1):90-5. PubMed ID: 8418017 [TBL] [Abstract][Full Text] [Related]
15. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas]. Shao HL; Shen DH; Xue WC; Li Y; Yu YZ Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760 [TBL] [Abstract][Full Text] [Related]
16. RhoC is a major target of microRNA-93-5P in epithelial ovarian carcinoma tumorigenesis and progression. Chen X; Chen S; Xiu YL; Sun KX; Zong ZH; Zhao Y Mol Cancer; 2015 Feb; 14(1):31. PubMed ID: 25649143 [TBL] [Abstract][Full Text] [Related]
17. Expression and clinical role of small glutamine-rich tetratricopeptide repeat (TPR)-containing protein alpha (SGTA) as a novel cell cycle protein in NSCLC. Xue Q; Lv L; Wan C; Chen B; Li M; Ni T; Liu Y; Liu Y; Cong X; Zhou Y; Ni R; Mao G J Cancer Res Clin Oncol; 2013 Sep; 139(9):1539-49. PubMed ID: 23857189 [TBL] [Abstract][Full Text] [Related]
18. Loss of SerpinA5 protein expression is associated with advanced-stage serous ovarian tumors. Bijsmans IT; Smits KM; de Graeff P; Wisman GB; van der Zee AG; Slangen BF; de Bruïne AP; van Engeland M; Sieben NL; Van de Vijver KK Mod Pathol; 2011 Mar; 24(3):463-70. PubMed ID: 21102419 [TBL] [Abstract][Full Text] [Related]
19. Loss of p16INK4A expression in low-grade ovarian serous carcinomas. Schlosshauer PW; Deligdisch L; Penault-Llorca F; Fatemi D; Qiao R; Yao S; Pearl M; Yang Z; Sheng T; Dong J Int J Gynecol Pathol; 2011 Jan; 30(1):22-9. PubMed ID: 21131838 [TBL] [Abstract][Full Text] [Related]
20. p53 expression in ovarian borderline tumors and stage I carcinomas. Kupryjańczyk J; Bell DA; Yandell DW; Scully RE; Thor AD Am J Clin Pathol; 1994 Nov; 102(5):671-6. PubMed ID: 7942635 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]